Therapeutic Immunoadsorption and Conventional Plasma Exchange in ABO-incompatible Renal Transplant: An Exculpatory Evidence

• Published in: Curēus (Palo Alto, CA) Vol. 11; no. 5; p. e4787
• Main Authors: Agrawal, Soma, Chowdhry, Mohit, Makroo, Raj N, Nayak, Sweta, Gajulapalli, Shiva P, Thakur, Uday K, Agrawal, Ankit
• Format: Journal Article
• Language: English
• Published: United States Cureus Inc 30.05.2019; Cureus
• Subjects: Antigens; Apheresis; Drug dosages; Hospitals; Immunoglobulins; Infections; Miscellaneous; Patients; Plasma; Transplantation; Transplants & implants; United States > US; India; abo incompatible; immunoadsorption; renal transplant
• ISSN: 2168-8184; 2168-8184
• DOI: 10.7759/cureus.4787

Aim The objective of this study was to compare the efficacy of immunoadsorption (IA) with conventional therapeutic plasma-exchange (cTPE) in ABO-incompatible (ABOi) renal transplant. Methods Data of patients from July 2015 to June 2017 (category-I, number of patients (N) = 11; IA±cTPE) on the average length of stay (ALOS), number of cTPE/IA, antibody-titers (AT), creatinine, patient and graft survival at one year were compared retrospectively with patients in period from February 2012 to June 2015 (category-II, N = 29; cTPE only). AT of patients not decreasing to less than one fold after two cTPE were shifted for IA. For patients undergoing IA, real-time AT was done and IA stopped after target titer (TT <1:8) was achieved. Post-transplant cTPE was done if, titers rebounded to ≥1:8. Intravenous immunoglobulin (IVIG) was given after every cTPE/IA. Cost comparisons were made. Results In category-I, seven patients (63.63%) were shifted to IA from cTPE. The mean cTPE procedures in category I and II are 3.5 ± 2.4 and 4.8 ± 2.5, respectively ( = 0.206). The mean IA procedures in category-I are 1.6 ± 0.5. The number of patients requiring post-operative TPE was less in category-I than category-II, i.e., = 5, 45.5% vs = 20, 69%, respectively ( = 0.171). The expense of IA in category-I vs cTPE in category-II was statistically not significant ( = 0.422) but had significant lesser ALOS ( = 0.044). Expenses, when a patient undergoes both cTPE and IA (category-I), are significantly higher to category-II ( = 0.003). The two groups were comparable in AT, creatinine value, graft and patient survival rates at one year. Conclusion Contrary to the general judgment of IA being expensive than cTPE, this study shows equivalent expenditures with comparable therapeutic outcomes.